Mesenchymal Stem Cells in Early Entry of Breast Cancer into Bone Marrow by Corcoran, Kelly E. et al.
Mesenchymal Stem Cells in Early Entry of Breast Cancer
into Bone Marrow
Kelly E. Corcoran
1, Katarzyna A. Trzaska
1, Helen Fernandes
2, Margarette Bryan
1, Marcelo Taborga
1,
Venkatesh Srinivas
1, Kathryn Packman
3, Prem S. Patel
4, Pranela Rameshwar
1*
1Department of Medicine, New Jersey Medical School-UMDNJ, Newark, New Jersey, United States of America, 2Department of Pathology and Laboratory Medicine, New
Jersey Medical School-UMDNJ, Newark, New Jersey, United States of America, 3Discovery Oncology, Hoffmann-La Roche, Nutley, New Jersey, United States of America,
4Brookdale University Hospital and Medical Center, Division of Trauma, Brooklyn, New York, United States of America
Abstract
Background: An understanding of BC cell (BCC) entry into bone marrow (BM) at low tumor burden is limited when
compared to highly metastatic events during heavy tumor burden. BCCs can achieve quiescence, without interfering with
hematopoiesis. This occurs partly through the generation of gap junctions with BM stroma, located close to the endosteum.
These events are partly mediated by the evolutionary conserved gene, Tac1.
Methodogy/Principal Findings: This study focuses on the role of mesenchymal stem cells (MSCs), Tac1, SDF-1 and CXCR4 in
BCC entry into BM. The model is established in studies with low numbers of tumor cells, and focuses on cancer cells with
low metastatic and invasion potential. This allowed us to recapitulate early event, and to study cancer cells with low invasive
potential, even when they are part of larger numbers of highly metastatic cells. A novel migration assay showed a
facilitating role of MSCs in BCC migration across BM endothelial cells. siRNA and ectopic expression studies showed a central
role for Tac1 and secondary roles for SDF-1a and CXCR4. We also observed differences in the mechanisms between low
invasive and highly metastatic cells. The in vitro studies were verified in xenogeneic mouse models that showed a
preference for low invasive BCCs to BM, but comparable movement to lung and BM by highly metastatic BCCs. The
expressions of Tac1 and production of SDF-1a were verified in primary BCCs from paired samples of BM aspirates and
peripheral blood.
Conclusions/Significance: MSC facilitate BCC entry into BM, partly through Tac1-mediated regulation of SDF-1a and CXCR4.
We propose a particular population of BCC with preference for BM could be isolated for characterization. This population
might be the subset that enter BM at an early time period, and could be responsible for cancer resurgence and resistance to
current therapies.
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Introduction
Tac1 has been linked to breast cancer (BC) development, and
invasion into bone marrow (BM) ([1–4]. Tac1 is ubiquitously
expressed, including nervous and hematopoietic systems [5,6],
where its encoded peptides bind to 7-transmembrane, G-protein
coupled receptors, neurokinin-1 (NK1), NK2 and NK3 [5–8]. The
major and most studied Tac1 peptide is substance P (SP) [9].
Indirect effects of Tac1 peptides can be partly explained by
cytokine production [5,9].
BC cells (BCCs) express two variants of NK1 with opposing
effects on BC development ([2]. Tac1 is also involved in
tumorigenesis through radiation resistance, protection from
apoptosis, and induction of growth- and angiogenic-promoting
factors [10]. Tac1 has a central role in BCC entry into BM of nude
mice [3]. In BM, when the frequency of BCC is low, Tac1
mediates the cells’ transition to quiescence among stroma, which is
located close to the endosteum and also prevent disrupted
hematopoiesis [3,11]. Thus, Tac1 appears to be central to cancer
remission, and also during low tumor burden at an early period,
and perhaps prior to clinical detection.
A role for Tac1 during entry of low invasive and highly
metastatic BCCs into BM has not been studied. We report on
studies that determined the mechanisms by which mesenchymal
stem cells (MSCs) facilitate BCC entry across the blood vessels into
BM. MSCs surround the abluminal vasculature of BM and are
therefore poised to interface the periphery and BM cavity [12,13].
Furthermore, MSCs are immune suppressors and could therefore
prevent immune clearance of few BCCs, which would be expected
during an early period and at low tumor burden [14,15]. Here we
show Tac1 as a mediator in the coupling of BCCs and MSCs and
their migration across BM endothelial cells. The coupling is shown
to be partly mediated by double interaction between SDF-1a and
its receptor CXCR4 ([16]. SDF-1a belongs to the chemokine
PLoS ONE | www.plosone.org 1 June 2008 | Volume 3 | Issue 6 | e2563family and is ubiquitously expressed [17]. CXCR4 is a seven-
transmembrane, G-protein coupled receptor that is involved in
chemoattaction of BCCs to organs of high SDF-1a [17–21].
Results
Interactions between BCCs and MSCs
T47D and MCF7 were selected to recapitulate BCC invasion
into BM [22], and compared with the highly metastatic, SDF-1
null
MDA-MB-231 and non-tumorigenic MCF12A [22]. BCCs have
been observed to adhere onto MSCs by bilayered method
(Figure 1A, inset). A fluorescenc-based quantitative method of
adherence showed significantly (p.0.05) higher mean fluorescence
intensities (6SD, n=5) for MCF7 and T47D as compared to
MCF12A with the highest intensities for MDA-MB-231
(Figure 1A).
Role of MSCs in Transmigration of BCCs across BM
endothelial cells
We established a migration assay to mimic BCC entry into BM
across BM endothelial cells and MSCs (Figure 1B, inset).
Fluorescence-labeled cells (10
4) were placed in the inner chamber
and transmigrated cells were determined from a standard curve,
established with BCCs vs. fluorescence intensities. In the absence
of MSCs, the migrations of all BCCs (p,0.05) were significantly
reduced (Figure 1B). Despite the reduction, MDA-MB-231
showed significant (p,0.05) migration in the absence of MSCs
as compared to MCF7 and T47D (Figure 1B). In summary, MSCs
increased the efficiency of MCF7 and T47D migration through
BM endothelial cells, suggesting that the role of MSCs might vary
depending on the relevant invasive and metastatic potential of
BCCs.
SDF-1 and CXCR4 expression in BCCs
SDF-1a and CXCR4 mRNA levels were significantly (p,0.05)
increased in MCF7 and T47D as compared to MCF12A
(Figures 2A and 2B). CXCR4 mRNA was significantly (p,0.05)
increased in MDA-MB-231 as compared to MCF7 and T47D
(Figure 2B). SDF-1a was undetectable, which is consistent with the
literature (Figure 2B) [22].
We next examined membrane-bound SDF-1a since this would
be relevant for interaction with CXCR4-expressing MSCs [23].
Western blots with membrane extracts showed strong bands for
SDF-1a in all cell lines except MDA-MB-231 (Figure 2A, inset).
Re-probing for CXCR4 showed light bands for MCF12A and
dense bands for the other cell lines (Figure 2B, inset). Normali-
zation with b-actin indicated direct proportion between CXCR4
expression and the cells’ aggressiveness, whereas the expressions
were similar for MCF7 and T47D.
Role of CXCR4 on BCC adherence and migration
A role for CXCR4 in the adherence and migration of BCCs was
studied in cells where CXCR4 was stably knockdown, which was
verified by western blots with combined whole cell and membrane
extracts (Figure 3A, right lanes). CXCR4 knockdown showed
significantly (p.0.05) reduced adherence of T47D and MDA-MB-
231 to MSCs (Figure 3C) as compared to mutant siRNA and
untransfected cells (Figure 3C). Migration studies showed similar
observations (Figure 3D). In summary, CXCR4 has roles in the
adherence of BCCs to MSCs and migration across BM
endothelial-MSCs bilayers.
SDF-1a-CXCR4 interactions between BCCs and MSCs
We next asked whether double interactions between CXCR4
and SDF-1a are involved in MSC-BCC complexes [24,25]. To
focus, we selected T47D and omitted MDA-MB-231 since they
are SDF-1
null [26]. SDF-1 or CXCR4 was knockdown in T47D
and MSCs and verified gene silencing by western blots (Figures 3A
and 3B). There was significant (p.0.05) reduction in migration
when MSCs or T47D was knockdown for SDF-1 as compared to
mutants or untransfected cells (Figure 3E). Similar observations
were noted for CXCR4 (Figure 3F). This section showed reduced
migration in conditions where SDF-1 or CXCR4 was knockdown
in MSCs or T47D.
Role of Tac1 on adhesion and migration of BCCs
A critical role has been reported for Tac1 in BCC entry to BM
of nude mice [3]. We now begin to ask whether this could be
explained by reduced adherence between BCCs and MSCs. Tac1
expression was determined by the level of its major peptide, SP
Figure 1. Adhesion and transmigration of BCCs. A. Image is
shown of bilayered adherence between MSCs and T47D. B. The
adherence of MCF12A, MCF7, T47D and MDA-MB-231 to MSCs are
presented as the mean fluorescence intensities, n=5. Each experiment
was done with MSCs from a different donor. C. Migration of BCCs across
BM endothelial cells with or without MSCs placed on the lower side of
the insert (Refer to inset). The results are presented as the mean percent
migration6SD, n=5. * p,0.05 vs. assays with MSCs.
doi:10.1371/journal.pone.0002563.g001
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T47D, 215610; MDA-MB-231, 755620. These values were
reduced to ,0.02 pg/mL in Tac1 knockdown cells and was
unchanged in untransfected and vector-transfectants.
To focus on further studies with Tac1 knockdowns, we
arbitrarily selected T47D as a low invasive line to compare with
MDA-MB-231. Cell adhesion assays showed significant (p.0.05)
decrease for knockdowns as compared to untransfected and vector
transfectants (Figure 4A). Similarly, Tac1 knockdown showed
significant (p.0.05) decreases in migration (3-fold) as compared to
untransfected and siRNA mutants (Figure 4B). In summary the
results show a role for Tac1 in the adherence and migration of
T47D and MDA-MB-231.
Role of SDF-1a and CXCR4 in the migration of Tac1
knockdown BCCs
This section determined whether reduced adherence and
migration of Tac1 knockdown BCCs could be explained by
changes in SDF-1 and/or CXCR4 expressions. CXCR4 expres-
sions (Figure 5A) were significantly (p,0.05) reduced in the Tac1
cells (Figure 5A). MDA-MB-231
null served as negative control.
SDF-1a levels over a 24-h period by confluent T47D were
significantly (p,0.05) reduced in Tac1 knockdown as compared to
vector transfectants and untransfectants (Figure 5B). In summary,
Tac1 knockdown led to reduced SDF-1a production in T47D and
lowered CXCR4 expression in both T47D and MDA-MB-231.
SDF-1a and/or CXCR4 were re-expressed in Tac1 knock-
downs to determine if this can over-ride the negative effects of
Tac1 silence with regards to adherence and migration (Figure 5C).
CXCR4 expression restored the migration of Tac1 knockdown
T47D, but only partly for MDA-MB-231 (Figure 5D, right
diagonal bars), whereas SDF-1a expression showed no difference
(Figure 5D, hatched bars). Co-expressions of SDF-1a and CXCR4
in T47D reverted cell migration (Figure 5D, vertical line bars),
similar to transfectants with CXCR4 alone (Figure 5D, right
hatched bars). The results were specific based on the results with
mutant siRNAs (not shown). In summary, CXCR4, but not SDF-
Figure 3. Role of CXCR4 and SDF-1 in BCC migration and
adherence. A. Representative of three western blots for CXCR4 and
SDF-1a with combined whole cell and membrane extracts from T47D,
and CXCR4 for MDA-MB-231. Lanes 1: Untransfected; 2: mutant siRNA; 3:
wild-type siRNA. B. Representative of three western blots for SDF-1a
(left panel) from three cell passages, and SDF-1a and CXCR4 for MSCs,
each from a different donor. C. Adherence studies with T47D and MDA-
MB-231 as untransfected, CXCR4 knockdown and control with mutant
siRNA, are presented as the mean fluorescence6SD, n=5. D. Migration
studies were done with the same cells and the results presented as
mean % migration6SD, n=5. *p,0.05 vs. untransfected or mutant
siRNA or wild-type siRNA. E. Migration studies with T47D, and MSCs
knockdown for SDF-1a or mutant siRNA, or untransfected. F. Migration
studies were similarly done with CXCR4 knockdown cells. The results
are presented as the mean % migration6SD, n=5. *p,0.05 vs.
untransfected or mutant siRNA.
doi:10.1371/journal.pone.0002563.g003
Figure 2. Relative expression levels of CXCR4, and SDF-1a
mRNA in BCCs. SDF-1a (A) and CXCR4 (B) mRNA levels were
quantitated in BCCs and presented as mean6SD, n=5. Representative
of four western blots for SDF-1a (A, inset) and CXCR4 (B, inset) with
membrane extracts from four different cell lines.
doi:10.1371/journal.pone.0002563.g002
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partly for MDA-MB-231.
In vivo verification
This section recapitulates BCC invasion, including an early
period of BC. The endpoints are categorized as positive vs.
negative, based on the detection of gDNA for b-globin by real-
time PCR at 72 h post-injection. b-globin primers did not cross-
react with murine gDNA and sensitivity of 1 human cell:10
6
murine cells (Figure S1). Time course studies at 24 h, 48 and 72 h
for cells in all tissues, peripheral blood, BM, lungs and liver.
Although BCCs were detected in BM at 24 h, only the 72-h results
were consistent, i.e., each femur within a group was positive. We
therefore designate 72 h as the optimum time for studies of BCCs
in BM.
The total number of mice positive at the cellular and endosteal
regions was significantly (p,0.05) reduced in Tac1 knockdowns
(Table 1). The detection of human gDNA was not due to cell
fusion between human and murine cells since immunohistochem-
istry with anti-cytokeratin showed intact BCCs in sections from
paraffin-embedded femurs (Text S1, Figure S2). The detection of
human gDNA is consistent with the results of PCR with gDNA
from peripheral blood (Table 1).
We asked if the facilitating role of Tac1 could be replaced with
expressions of SDF-1a and CXCR4. We therefore injected mice
with Tac1 knockdown T47D and MDA-MB-231 that were
expressed for SDF-1a and/or CXCR4. While SDF-1a expression
showed significantly (p,0.05) more positive femurs for MDA-MB-
231, CXCR4 expression led to significant (p,0.05) increase for
T47D (Table 1A). Their co-expressions caused an increase in
positive femurs, but not to the level of Tac1 expression (Table 1A).
Also, T47D Tac1 knockdown cells were less efficient in migrating
to the endosteum. Of significance is the detection of MDA-MB-
231 after 48 h in lungs whereas T47D was undetectable in lungs
even at 72 h (Table 1B). This suggests that T47D shows
preference for BM.
We next determined if MSCs are in close location of BCCs in
femurs. This was addressed in triple labeled immunohistochem-
istry for MSCs and BCCs with sections from longitudinal paraffin-
embedded femurs of mice injected with T47D for 72 h. Stainings
were done for cytokeratin (FITC-green); endothelial cells (CD31-
blue) and endothelial/MSCs (CD105-red). Co-labelings for CD31
and CD105 (purple) indicate blood vessel, and/or vessels with
surrounding MSCs. Cytokeratin (+) cells in close contact with
MSCs (yellow) suggesting close location between MSCs and
BCCs. Figure S3, white arrows indicate where BCCs are in close
contact with MSCs, based on co-labeling.
The next set of immunohistochemistry labeled slides at an
earlier time point at 24, 48 and 72 h as for Figure S3. The mice
were injected with T47D: untransfected, Tac1 knockdown; Tac1
knockdown, with SDF-1a and/or CXCR4 re-expressed. Figure 6
shows representative labeling for 24-h injections. The early time
point was selected because MSCs are expected to be coupled to
BCCs before the cancer cells move towards the endosteum. The
slides were triple labeled for cytokeratin (green) and MSCs (red).
Since endothelial cells are also positive for CD105, co-labeling for
CD31 (blue) served as a marker to discriminate MSCs from
endothelial cells. The results are shown for labeling in the cellular
region. The images (top panel, left) show yellow labeling for T47D
transfected with vector alone, indicating close location between
CD105 (MSCs or endothelial cells) and cytokeratin (BCCs)
positive cells. Since the yellow image was away from CD31
(blue/endothelial cells), the CD105 represented MSCs. Untrans-
fected T47D showed similar findings (not shown). Cytokeratin cells
were not detectable in the Tac1 knockout cells (top panel, right).
Arrows show detectable BCCs in close location with MSCs when
SDF-1a and/or CXCR4 were/was re-expressed.
Substance P-SDF-1a interactions
Re-expression of SDF-1a in the Tac1 knockdown correlated
with enhanced presence of BCCs in the femurs of mice (Table 1).
We therefore asked the expressions of Tac1 and SDF-1 involves
autocrine stimulations. To address this question, we first asked if
exogenous SDF-1a (50 ng/mL) enhances the production of
substance P in T47D and MDA-MB-231. In addition, we also
studied substance P expression in primary BCCs with different
stages of BC. Since SDF-1a has been shown to induce the
production of substance P in non-tumorigenic MCF12A [27], its
stimulation served as control (Table 2). The results show
significant increases in substance P for both cell lines and all
primary BCCs (Table 2). Interestingly, baseline and induced SDF-
1a levels were increased in the late stage disease.
Figure 4. Effects of Tac1 on adhesion and transmigration of
T47D. A. Adhesion of Tac1 knockdown T47D and MDA-MB-231, vector
transfectants or untransfected cells. B. Transmigration studies with the
cells described in ‘A’. Results are presented as mean6SD, n=5.
* p,0.05 vs. untransfected or vector transfectants.
doi:10.1371/journal.pone.0002563.g004
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expression on SDF-1a production was addressed in knockdown
studies. Since MDA-MB-231 is null for SDF-1, the studies were
addressed with T47D, knockdown for Tac1. SDF-1a levels were
significantly (p,0.05) decreased in the knockdown cells as
compared to untransfected and siRNA mutant (Table 3),
indicating that Tac1 expression is involved in the production of
SDF-1a. Since BCCs also express other cytokines [3], we verified
that Tac1 is indeed involved in the production of SDF-1a in a
defined model. Thus, we express Tac1 in MCF12A and then
Table 1. Effects of Tac1, SDF-1a and CXCR4 in BCC entry into
BM.
A. EXPERIMENTAL GROUPS BM PB
Cellular Endosteal
T47D
Cell alone 18 18 14
Tac1 mut 16 18 16
Tac1 knockdown 1 2 5
- SDF-1a 61 06
- CXCR4 16 19 12
- SDF-1a/CXCR4 16 6 14
MDA-MB-231
Cells alone 14 15 15
Tac1 mut 16 16 16
Tac1 knockdown 0 1 1
- SDF-1a 14 10 10
- CXCR4 4 4 4
- SDF-1a/CXCR4 10 10 10
Vehicle (PBS) 0 0 0
B. Organs Time (h) T47D MDA-MB-231
Lung 24 0/20 15/20
48 0/20 18/20
72 0/20 17/20
Endosteum 24 5/20 5/20
48 10/20 6/20
72 18/20 11/20
BM: Bone Marrow; PB: Peripheral Blood.
A. Nude mice (n=20) were injected with 10
4 BCCs in the mammary fat pad as
untransfected, Tac1 knockdown, with SDF-1a and/or CXCR4 expressions. At
various times, cells from the central region of femurs (Cellular) and those close
to the endosteum (Endosteal) were analyzed by real-time PCR for human
genomic b-globin (Figure S1). The results are shown for 72 h time points. B.
Analyses similar ‘A’ were done with gDNA from lungs and endosteal regions of
the BM.
doi:10.1371/journal.pone.0002563.t001
Figure 5. Migration with Tac1 knockdown T47D and MDA-MB-
231, expressed with CXCR4 and/or SDF-1a.A .Cells were analyzed
for CXCR4 by flow cytometry (n=4). B. SDF-1a production by ELISA,
mean6SD, n=5. *p,0.05 vs. untransfected for vector-transfected T47D.
C. Western blots with whole cell lysates from Tac1 knockdown cells
and/or expressed for SDF-1a and/or CXCR4 (Lanes 1: Tac1 siRNA; 2: Tac1
siRNA+SDF-1a;3 :Tac1 siRNA+CXCR4; 4: Tac1 siRNA+SDF-1a+CXCR4. D.
Transmigration assays with T47D and MDA-MDB-231 and their variants
as for ‘A’. * p,0.05 vs. Tac1 siRNA. ** p.0.05 vs. Tac1 siRNA.
doi:10.1371/journal.pone.0002563.g005
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cells. The results showed significant production of SDF-1a in the
expression cells as compared to T47D, untransfected and vector
transfectants (Table 4). In summary, the results showed autocrine
stimulations by SDF-1a and the major Tac1 peptide, substance P
in T47D.
Finally, we determined whether Tac1 is expressed in BCCs
within BM, and also determined how its expression differs from
BCCs in the peripheral blood of the same patients. Since the
criteria were to get samples at diagnosis, before treatment, we were
able to acquire five patients with Stage III BC (P15–P19). RT-
PCR for Tac1 mRNA showed bright bands for cytokeratin
positive cells in BM aspirates (Figure 7A). Similar studies with
cytokeratin expressing cells in peripheral blood showed dim bands
(Figure 7B). Despite the small cohort of patients, these results
suggest that Tac1 expression might be enhanced when the BCCs
enter BM, or alternatively, Tac1-expressing cells might show
preference for BM.
Discussion
This study reports on a BC model that recapitulates an early
period when the tumor burden is low, in remission and/or has
invaded BM. The model used the low invasive cell lines, MCF7
and T47D and compared with the highly aggressive SDF-1
null
MDA-MB-231 [22,26]. The report show a central role for Tac1,
and a potential facilitating role for MSCs for BCC entry into BM.
Tac1 mediates its effects via SDF-1a and CXCR4. A most
interesting finding is the differences observed between the low and
highly aggressive BCCs. While Tac1 is relevant for the biology of
both, the involvement of SDF-1a, CXCR4 and MSCs was more
relevant for the low invasive lines (Figure 1 and Table 1). Re-
expressions of CXCR4 and SDF-1a in Tac1 knockdown MDA-
MB-231 were insufficient to reverse Tac1 silence (Figures 3 and 5).
CXCR4, but not SDF-1a was sufficient to replace the loss of Tac1
in T47D in migration (Figure 5D). These differences suggest
variations at different stages of BC.
The findings underscore relevance for CXCR4 in migration of
low metastatic BCCs into BM at low tumor burden, or for a
specific population of BCCs during high tumor burden. These
differences are important, in particular for the subset that exists
during low tumor burden. This population might be responsible
for cancer resurgence and could also begin to device translational
studies with combinations of available CXCR4 and Tac1 peptide
receptor antagonists. CXCR4 activation depends on the aggres-
siveness of BCCs [28]. Tac1 peptides and CXCR4 both activate
G-protein coupled receptors [10]. Thus, indepth research studies
are required to determine how these receptors are involved in the
Table 2. Induction of substance P by SDF-1a in BC cell lines
and primary BC cells.
Cells Substance P (pg/mL)
Unstimulated Stimulated
MCF12A 0.00160.0001 71.665*
T47D 220610 565618*
MDA-MB-231 725632 1510625*
P1, P2, P3 (Stage IIIA) 310622 645625*
P11, P12 (Stage M0) 162610 445618*
P9, P10 (Stage I) 85651 6 0 68*
Confluent cells were stimulated for 24 h with 50 ng/mL of SDF-1a in sera-free
media. ELISA quantitated the levels of substance P in the culture media. The
results are presented as mean substance P levels (pg/mL)6SD. Each cell type
was analyzed five times with different cell passages.
*p,0.01 vs. unstimulated cells.
doi:10.1371/journal.pone.0002563.t002
Table 3. SDF-1a production in Tac1 knockdown T47D.
Cells SDF-1a (pg/ml)
Untransfected 1108612
Tac1 knockdown 10565*
siRNA vector alone 121565
siRNA mutant 1220615
T47D cells were stably knockdown for Tac1. Controls were transfected with
mutant siRNA. At 80% confluence, culture media were replaced with fresh
media and after aliquots of media were collected and then quantitated for SDF-
1a levels by ELISA. The results are presented as the mean6SD of four different
experiments.
*p,0.05 vs. all other experimental points.
doi:10.1371/journal.pone.0002563.t003
Table 4. SDF-1a production in Tac1-expressing MCF12A.
MCF12A SDF-1a (pg/mL)
Untransfected 0.002
Tac1 expression 66614*
Vector alone 0.001
Tac1 was ectopically expressed in MCF12A. At 80% confluence, media were
replaced. After 24 h, aliquots of media were quantitated for SDF-1a levels by
ELISA.
*p,0.05 vs. untransfected and vector transfectant.
doi:10.1371/journal.pone.0002563.t004
Figure 6. Representative of three sections obtained from
femurs nude mice after 24 h of injections with T47D,
untransfected, knockdown (KO) for Tac1; Tac1 knockdown
with re-expressions of SDF-1a and/or CXCR4. The femurs were
treated as described for Figure S1 and the slides were triple labeled as
for Figure S3 with PE-anti-CD105, FITC-anti cytokeratin and APC-anti-
CD31. Arrows in the merged images depict cytokeratin (+) cells in
contact with MSCs (green and red), but not in contact with CD31+ cells
(blue).
doi:10.1371/journal.pone.0002563.g006
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coupling to MSCs, and finally migration towards the endosteum.
The in vivo studies have been analyzed by a sensitive method to
detect human gDNA in BM and lung (Figure S3 and Table 1).
Expression of SDF-1a in Tac1 knockdown MDA-MB-231 showed
no difference in their adherence to MSCs or migration by in vitro
methods (Figure 5D), but by in vivo studies, SDF-1a showed
restoration in the cells’ ability to enter BM (Figure 5D, and
Table 1A). This observation indicates that other unidentified in vivo
factors might be involved in BM metastasis and/or invasion by
highly metastatic cells such as MDA-MB-231. In contrast, co-
expressions of SDF-1a and CXCR4 in Tac1 knockdown T47D led
to an increase in the number of mice with BCCs in femurs,
although reversion was not absolute.
An increase in the number of positive femurs with SDF-1a
expressing Tac1 knockdown MDA-MB-231 suggests an advantage
for BCCs where SDF-1a production is reduced. Perhaps SDF-1a
might occupy CXCR4 through autocrine binding. By occupying
CXCR4, the BCCs might lose their efficiency to metastasize
towards organs of concentrated SDF-1a.
MDA-MB-231 was detected at an early time point in both BM
and lung whereas T47D was only detected in BM (Table 1B).
These observations, although preliminary, suggest that the
combined in vitro and in vivo models might be suitable to study
the early event of BCC entry into BM, and might also be relevant
for the biology of BCCs during low tumor burden without
evidence of metastasis.
While CXCR4 is relevant for interaction between BCCs and
MSCs, we cannot eliminate the possibility of molecular redun-
dancy and also the involvement of other molecules. Tac1
knockdown BCCs could still migrate although less, suggesting
the involvement of other molecules (Figure 4B). We propose
CXCR4 antagonists might be ideal for patients who have been
diagnosed early and show no lymph node involvement [29]. This
would be a prudent measure to prevent low numbers of BCCs to
enter BM.
Previous studies have reported BCCs with varying cycling
properties, based on their location in BM [3]. In this study, we
have subjected the femurs to strong wash before the cells were
scraped, indicating strong attachment of BCCs to the endosteal
compartment where hematopoietic stem cells are located. While
information is beginning to emerge on the mechanisms by which
BCCs are able to retain hematopoietic homeostasis through gap
junctions and changes in SDF-1a levels [11], robust analyses are
required to determine how various stages of the hematopoietic
hierarchy are affected by the two major subsets of BCCs, and also
to characterize them at the molecular and phenotypic levels. In
addition, further studies are required to understand how gap
junctions affect the properties of BCCs with BM cells and bone
[11,30,31].
Roles for MSCs during an early period of BC need
consideration, especially since others have supported BM aspirates
for early diagnosis [32]. MSCs surround the abluminal surface of
the blood vasculature of BM could act against the immune system
and protect BCCs in BM [12,13,32]. If the entering BCCs have
relatively few mutations, this population is likely to be protected by
MSCs [33–36]. We emphasize that the proposed role for MSCs at
an early period and/or at low tumor burden is different from
metastasis [37].
In contrast to roles for CXCR4 in BC metastasis [26], this study
focuses on its role during an early period, including a role during
entry into BM and the potential involvement of MSCs at the
interface between the BM and periphery. Although the in vitro
studies show a facilitating role for MSCs in the migration of BCCs,
a definitive role for MSCs is still to be determined. The in vivo
studies show close locations between BCCs and MSCs. Since
depletion of MSCs could lead to overt vascular damage, it is
difficult to show a role for MSCs. An understanding of relevant
molecules in the interactions between BCCs and MSCs will allow
for future studies to have definitive answers for the role of MSCs in
BCC survival and quiescence in BM. This report has underscored
future studies to track the movement of BCCs in live animal using
imaging with luciferase expressing cells.
The study has raised questions on drug combinations with
CXCR4 and Tac1 receptor antagonists for both low and highly
metastatic BCCs. Figure S4 summarizes the findings and show
BCCs entering BM and interacting with MSCs through double
interactions between SDF-1a and CXCR4. Upon entry, all or few
BCCs reach the endosteum to form gap junctions with BM stroma
[11]. While we have studied SDF-1a, other isoforms might be
involved [37]. An understanding of the mechanisms by which
BCC enter and survive in BM could lead to pertinent treatments,
detection, and methods to ‘flush’ BCCs from BM for eradication.
An understanding of BCC survival in BM is significant since BC
could resurge after ten years of remission, and is associated with
poor prognosis [38,39].
Materials and Methods
Mice
Female athymic BALB/c mice (4 weeks) were obtained from the
National Cancer Institute (Bethesda, MD) and housed in a laminar
flow hood at an AALAC-accredited facility. The use of mice was
approved by the Institutional Animal Care and Use Committee,
New Jersey Medical School (Newark, NJ). BCCs (10
4) were
injected into the left, hind mammary fat pad, and then euthanized
at 48 and 72 h post-injection. BM cells designated as those from
cellular region were obtained by slowly flushing femurs with media
through a syringe, attached to a 26 g needle. Cells designated as
those in the endosteal regions were obtained by opening femurs
longitudinally and then scraping the cells attached to the inner
surfaces.
Cells
The following cell lines were purchased from American Type
Culture Collection (www.atcc.org): MCF-7, T47D, P815,
MCF12A and MDA-MB-231. MSCs were cultured from human
BM aspirates in DMEM with 10% FCS (D10 media), as described
[14]. The use of human BM aspirates followed a protocol
Figure 7. Tac1 mRNA in cytokeratin-expressing cells from BM
aspirates and peripheral blood of Stage III BC patients. Pairs of
BM aspirates (A) and peripheral blood (B) were taken from BC patients
at the time of diagnosis. Cytokeratin positive cells were selected and
then subjected to RT-PCR for Tac1 mRNA and GAPDH.
doi:10.1371/journal.pone.0002563.g007
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Newark campus). The MSCs were adherent cells, morphologically
symmetric, CD14
2, CD29
+, CD44
+, CD34
2, CD45
2, SH2
+, and
negative for prolyl-4-hydroxylase [15].
Primary BCCs
The following samples were obtained from five different patients
with Stage III BC (P15–P19) at Brookdale Hospital, Brooklyn, NY
and at University Hospital, University of Medicine and Dentistry of
New Jersey (UMDNJ), Newark, NJ: breast tissues from surgical
specimens; peripheral blood cells and BM aspirates. The samples
were left-over from diagnostic procedures, before treatment. The use
of tissues was approved by the institutional review board of Brookdale
Hospital and UMDNJ. The samples were obtained before the
patients were placed on treatments with anti-cancer agents. The
demographics of Patients 15–19 (P15–P19) were as follows: Age
ranges between 45 and 62 yrs; P15–P18 were positive for estrogen
(ER) and progesterone (PR) receptors and Herceptin (HER2)
negative. P19 was negative for ER and PR and HER (+). Surgical
tissues and peripheral blood samples were obtained from P15–17.
Peripheral blood and BM aspirates were taken from P18 and P19.
The hormone status and age of Stage IIIA patients 1–3 (P1–P3);
Stage M0, P11 and P12 and Stage 1, P9 and P10 were previously
reported [2,3]. The malignant cells from these patients were
expanded from surgical tissues, as described [40].
BM Endothelial Cells (BMECs)
BMECs were cultured from BM aspirates of healthy individuals,
as outlined by a protocol approved by the IRB-UMDNJ.
Mononuclear cells were separated by Ficoll-Hypaque density
gradient and then plated in fresh endothelial medium (Cambrex,
Boston MA). Cells were incubated until confluence (,3 weeks).
Media (50%) were replaced with fresh lot at weekly intervals. Flow
cytometry indicated that .95% at passage 5 were positive for
vWF and CD31.
Vectors
pPMSKH1/Tac1 was previously described [3]. pPMSKH1-
SDF-1/KC, an SDF-1-specific siRNA vector was constructed as
previously described [3]. Mutants contained three single base pair
changes: pPMSKH1-SDF-1/KM. pSUPER-CXCR4 (wild-type
and mutant) siRNA vectors were kindly provided by Dr. Si-Yi
Chen (Baylor University) [41]. CXCR4 expression vector was
kindly provided by Dr. Nelson Michael (Walter Reed Research
Institute) [42]. pEF2-SDF-1a expression vector contained the
coding region of Acc#L36034. pEF2 was provided by Dr. Sergei
Kotenko (UMDNJ) [43].
Stable Expressions
BCCs or MSCs were co-transfected with pTK-Hyg and
pPMSKH1-Tac1, pPMSKH1-SDF-1/KC, pPMSKH1-SDF-1/
KM, pSUPER-CXCR4 (mutant and wild-type), or pPMSKH1.
Transfectants were selected with hygromycin or G418. Tac1
knockdown showed undetectable SP by ELISA [3]. CXCR4
knockdown showed no evidence of membrane and intracellular
expressions by western blots. SDF-1 knockdown was confirmed by
negative RT-PCR.
Tac1 knockdown BCCs were stably transfected with CXCR-4
and/or SDF-1a expression vectors as described above. SDF-1a
expression was verified by ELISA and western blots as above, and
CXCR4 by flow cytometry and western blots with membrane
extracts. Flow cytometry studies were done with cells de-adhered
with Dissociation Solution (Sigma).
CXCR4 and SDF-1a mRNA Levels
CXCR-4 and SDF-1a mRNA levels were determined with
Quantikine mRNA kit (R&D Systems) using 5 mg of total RNA, as
per manufacturer’s instructions. Unknowns were calculated with
standards provided with the kit. The assay limits were 5 amol/mL
for both SDF-1a and CXCR-4.
Western Analyses
Membrane extracts were prepared with 2610
6 cells as de-
scribed [2], and 15 mg were analyzed by western blots on gradient
SDS-PAGE (BioRad). Proteins were transferred onto polyvinyl
membranes and then incubated first with primary antibodies, 1/
1000 final dilutions and then with secondary antibodies at 1/2000
dilutions. Bands were detected by chemiluminescence.
SP ELISA
ELISA quantitated SP as described [2]. At confluence, media
were replaced with 2% FCS-containing media. After 24 h, media
were collected and then quantitated by ELISA. Unknowns were
analyzed as undiluted and two serial dilutions, each studied as
triplicates. The unknowns were determined with a standard curve
established for each plate.
Cell Adhesion Assay
Adhesion of BCCs to MSCs was studied with the Cell Adhesion
Assay Kit (Invitrogen, Carlsbad, CA). MSCs (10
4/well) were
incubated overnight in 96-well plates. BCCs were labeled with the
fluorescent cytoplasmic tracer, Vybrant CFDA SE (Invitrogen) as
per manufacturer’s instructions and 10
3 were added to the
confluent MSC. Non-specific binding was studied in wells without
MSCs. After 15 min, the non-adherent cells were washed twice
with PBS and the adherent cells were detected by fluorescence on
the FL1500 Fluorescent Microplate Reader (Biotek, Winooski,
VT). Non-specific adherence was subtracted from the test wells.
Transmigration Assay
BCC migration used a Boyden chamber with 8 micron inserts.
The inner wells were inverted and 10
3 MSCs were added to the
filter in D10 media. The next day, the wells were overturned and
then placed into the outer chamber contained 500 mL of D10
media. BMECs (10
4) were added to the inner chamber in
endothelial media. The next day, BCCs were labeled with
CellTracker
TM Green CMFDA (5-chloromethylfluorescein diace-
tate) (Invitrogen) as per manufacturer’s instruction. Briefly, 10
6
BCCs were incubated for 15 min with 5 mM of CMFDA.
Labeling efficiency by fluorescence microscopy indicated .95%
labeling efficiency. BCCs (10
4) were added to the inner chamber in
sera-free DMEM. After 3 h, cells were washed twice with PBS.
The cells in the inner chamber were removed with a cotton swab
and 500 ml of PBS were added to the outer chamber. The inserts
were examined for fluorescence on the Typhoon (Amersham
Pharmacia, Molecular Dynamics, Sunnyvale, CA). The mean
fluorescence intensity for each well was quantitated using Image
Quant software and the percent cell migration was calculated on a
standard curve of total BCCs vs. fluorescence intensity.
Real-time PCR
gDNA was isolated from T47D (human) at log10 fold dilution
ranging from 10
4 to 1, added to 10
6 or 2610
6 P815 (murine).
gDNA quality was tested by standard PCR at 55uC for 40 cycles in
a GeneAmp PCR 9700 thermal cycler (Applied Biosystems, Foster
City, CA), Platinum Taq polymerase (Invitrogen) and murine IL-
10 primers, Acc#M37897, +1523/+1723. Real-time PCR for
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hormone with Roche Light Cycler 2.0. Gene specific primers and
probes were purchased as part of the Control Kit DNA for Light
Cycler. Each sample was analyzed in triplicate and the data
analyzed by Poisson’s law of small numbers in which one, two or
three positives were counted positive for human cells. PCR at 40
cycles/55uCT M showed consistent detection at 1 T47D:10
6 P815
with b-globin primers, but inconsistent results with growth
hormone primers. Thus, all analyses shown for the in vivo studies
were done with b-globin primers.
Semi-quantitaive RT-PCR
Cytokeratin expressing cells were isolated from BM aspirates
and peripheral blood of patients (P15–P19) as described [44].
Total RNA was isolated with the RNAqueous 4PCR kit (Ambion,
Austin, TX) and then subjected to reverse-transcription with
SuperScript III Reverse Transcriptase (Invitrogen). The cDNA
served as template to amplify Tac1 mRNA. PCR was done with
Platinum Taq Polymerase (Invitrogen) under the following
conditions: 95uC, 30 sec; 55uC, 30 sec; and 72uC, 30 sec for 35
cycles. The reaction was preceded by an initial denaturation at
95uC for 2 min and a final extension at 72uC for 10 min. PCR was
normalized by amplifying the same cDNA with primers for
GAPDH under similar PCR conditions. Tac1 primers span +60 to
+328 (NM_003182), 59-act gtc cgt cgc aaa atc-39 (sense) and 59-
ggg cca ctt gtt ttt caa-39 (antisense). GAPDH primers span +254 to
+851 (NM_002046), 59-cca ccc atg gca aat tcc atg gca-39 (sense)
and 59-tct aga cgg cag gtc agg tcc acc-39 (antisense). All PCR
reactions were analyzed by electrophoresis on a 1% agarose gel
containing ethidium bromide and fragment sizes were compared
with 1 kb plus DNA ladder (Invitrogen).
Statistical Analyses
Statistical evaluations were done with analysis of variance and
Tukey-Kramer multiple comparisons test. p,0.05 was considered
significant. For small numbers, the data were analyzed by Poisson
law of small numbers, and by binomial probability distribution
[45].
Supporting Information
Text S1
Found at: doi:10.1371/journal.pone.0002563.s001 (0.03 MB
DOC)
Figure S1 The sensitivity of detecting human gDNA was studied
with different ratios of T47D cells (human) to P815 (murine).
Representative graph shows the sensitivity of 1 T47D among 106
P815 (arrow).
Found at: doi:10.1371/journal.pone.0002563.s002 (0.07 MB
PDF)
Figure S2 Representative section from ten femurs of nude mice,
injected with T47D or MDA-MB-231. The femurs were sectioned
after 72 h of injection and then embedded as longitudinal sections.
A. Control comprised section of breast tissue from a patient with
Stage III BC, labeled with FITC-isotype control (right panel) or
FITC-anti-cytokeratin (left panel). B. Section from a femur
injected with T47D (left panel) or MDA-MB-231 (right panel).
Found at: doi:10.1371/journal.pone.0002563.s003 (0.09 MB
PDF)
Figure S3 Representative of five sections obtained from femurs
nude mice, injected with T47D. The femurs were treated as
described for Figure S1 and the slides were triple labeled with PE-
anti-CD105, FITC-anti cytokeratin and APC-anti-CD31. The
latter was done by indirect staining with APC-anti-mouse IgG.
Each primary and the secondary antibody were used at 1/2000
final dilution. MERGED figure shows arrows depicting cytoker-
atin (+) cells in contact with CD105+/CD31- cells.
Found at: doi:10.1371/journal.pone.0002563.s004 (0.09 MB
PDF)
Figure S4 Shown in cartoon, are untransfected BCCs, Tac1
knockdown BCCs, with SDF-1a or CXCR4 expressed, entering
the BM cavity, in complex with MSCs. While the untransfected
BCCs have been shown to form gap junctions with stromal cells
close to the endosteum (1). The fate of the other two BCCs to
reach the stromal compartment has not been shown, and is
currently unclear.
Found at: doi:10.1371/journal.pone.0002563.s005 (0.28 MB
PDF)
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